A study from Leipzig suggests that the growth factor GDF-15 could play a protective role in the development of fatty liver disease and scarring, especially in risk factors such as obesity, insulin resistance or high alcohol consumption. Researchers at the University of Leipzig analysed data from long-term observation and found different correlations depending on the cause of the liver damage.

In the retrospective study, 626 adults from a population study were considered over a period of six years. The scientists evaluated the influence of GDF-15 on liver stiffness as a marker of fibrosis as well as fat accumulation in the liver. They took into account metabolic risks such as the FIB-4 score for fibrosis, the body mass index and the HOMA-IR index for insulin resistance, as well as alcohol consumption.

In individuals with elevated baseline FIB-4 levels, GDF-15 was associated with an increase in liver stiffness, while there was a decrease in stiffness in groups with higher alcohol consumption. Separately, GDF-15 was directly related to more liver fat, but showed a attenuating effect on steatosis in severe insulin resistance. In subgroups with obesity or increased risk of fibrosis, these interactions were intensified.

The results suggest that GDF-15 could mitigate the progression of liver disease, especially in the case of metabolic stress or lifestyle factors. The study calls for further research into therapeutic approaches that benefit the neuro-metabolic-immune axes.

Important details can be seen as posters at the DKLM 2025 in Leipzig. Interested media can receive the poster in advance in compliance with the strict embargo period of 23.10.2025 / 00:01 and presentation of a valid press card. To do so, send us your enquiry including a copy of your press card to: redaktion@medlabportal.de

The German Congress of Laboratory Medicine (DKLM) 2025 promises exciting insights into the interface between science and clinical practice. Under the motto “Science for Precision Medicine”, the German Society for Clinical Chemistry and Laboratory Medicine (DGKL) and the Umbrella Association for Technologists and Analysts in Medicine Germany (DVTA) invite experts from research, clinics and industry to meet on October 23 and 24 at the Congress Center Leipzig (CCL). The two-day event is aimed at laboratory physicians, biomedical analysts and decision-makers to discuss current advances in diagnostics and strengthen networks. The ceremonial opening of the congress will take place on 22 October with the presentation of the MedLabAwards in the Salles de Pologne.

Editor: X-Press Journalistenbüro GbR

Gender Notice. The personal designations used in this text always refer equally to female, male and diverse persons. Double/triple naming and gendered designations are used for better readability. ected.